226992-13-8

Usage

Uses

Used in Organic Synthesis:
4-Nitro-N-[2-(4-nitrophenoxy)ethyl]benzeneethanamine is used as a key intermediate in organic synthesis for the production of various organic compounds. Its unique structure allows it to participate in a range of chemical reactions, facilitating the synthesis of complex molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-Nitro-N-[2-(4-nitrophenoxy)ethyl]benzeneethanamine is utilized as a building block for drug development. Its potential biological activity makes it a valuable component in the design and synthesis of new pharmaceuticals aimed at treating various diseases and conditions.
Used in Drug Development:
4-Nitro-N-[2-(4-nitrophenoxy)ethyl]benzeneethanamine is employed in the development of new drugs due to its potential to exhibit biological activity. Researchers leverage its chemical properties to create novel therapeutic agents that can address unmet medical needs.

Upstream product

• 13288-06-7 1-(2-bromoethoxy)-4-nitrobenzene 
• 69447-84-3 p-nitrophenethylamine hydrobromide 
• 100-02-7 4-nitro-phenol 
• 877-95-2 methyl-N-(benzyl-methyl)-formamide 
• 6270-07-1 N-<2-(4-nitrophenyl)ethyl>acetamide 
• 64-04-0 phenethylamine 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 

Downstream Products

• 248599-61-3 N-[2-(p-nitrophenoxy)ethyl]-N-[2-(p-nitrophenoxy)ethyl]-p-nitrophenethylamine 
• 176447-94-2 [Cy₃B]-N-Demethyldofetilide 
• 446877-49-2 N-allyl-N-[2-(p-nitrophenoxy)ethyl]-p-nitrophenethylamine 
• 226992-23-0 N-(p-chlorobenzyl)-N-[2-(p-nitrophenoxy)ethyl]-p-nitrophenethylamine 
• 446877-50-5 N-benzoyl-N-[2-(p-nitrophenoxy)ethyl]-p-nitrophenethylamine 
• 226992-14-9 N-benzyl-N-[2-(p-nitrophenoxy)ethyl]-p-nitrophenethylamine 
• 226992-21-8 N-acetyl-N-[2-(p-nitrophenoxy)ethyl]-p-nitrophenethylamine 

Relevant academic research and scientific papers

7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS

The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS

A compound of formula (I) or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE

The compound of formula (I) or a salt, preferably a pharmaceutically acceptable salt, thereof; is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate mast cell activation, for ins

New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: Design, synthesis, biological assay, and 3D-QSAR analysis

Class III antiarrhythmic agents selectively delay the effective refractory period (ERP) and increase the transmembrance action potential duration (APD). Using dofetilide (2) as a template of class III antiarrhythmic agents, we designed and synthesized 16 methylsulfonamido phenylethylamine analogues (4a-d and 5a-1). Pharmacological assay indicated that all of these compounds showed activity for increasing the ERP in isolated animal atrium; among them, the effective concentration of compound 4a is 1.6 × 10-8 mol/L in increasing ERP by 10 ms, slightly less potent than that of 2, 1.1 × 10-8 mol/L. Compound 4a also produced a slightly lower change in ERP at 10-5 M, ΔERP% = 17.5% (ΔERP% = 24.0% for dofetilide). On the basis of this bioassay result, these 16 compounds together with dofetilide were investigated by the three-dimensional quantitative structure-activity relationship (3D-QSAR) techniques of comparative molecular field analysis (CoMFA), comparative molecular similarity index analysis (CoMSIA), and the hologram QSAR (HQSAR). The 3D-QSAR models were tested with another 11 compounds (4e-h and 5m-s) that we synthesized later. Results revealed that the CoMFA, CoMSIA, and HQSAR predicted activities for the 11 newly synthesized compounds that have a good correlation with their experimental value, r2 = 0.943, 0.891, and 0.809 for the three QSAR models, respectively. This indicates that the 3D-QSAR models proved a good predictive ability and could describe the steric, electrostatic, and hydrophobic requirements for recognition forces of the receptor site. On the basis of these results, we designed and synthesized another eight new analogues of methanesulfonamido phenylethyamine (6a-h) according to the clues provided by the 3D-QSAR analyses. Pharmacological assay indicated that the effective concentrations of delaying the ERP by 10 ms of these newly designed compounds correlated well with the 3D-QSAR predicted values. It is remarkable that the percent change of delaying ERP at 10-5 M compound 6c is much higher than that of dofetilide; the effective concentration of compound 6c is 5.0 × 10-8mol/L in increasing the ERP by 10 ms, which is slightly lower than that of 2. The results showed that the 3D-QSAR models are reliable and can be extended to design new antiarrhythmic agents.